(Q44612816)

4 December 2017

WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics (English)

1 reference

4 December 2017

Steven M Grauer

1

1 reference

4 December 2017

Radka Graf

2

1 reference

4 December 2017

Rachel Navarra

3

1 reference

4 December 2017

Amy Sung

4

1 reference

4 December 2017

Sheree F Logue

5

1 reference

4 December 2017

Gary Stack

6

1 reference

4 December 2017

Christine Huselton

7

1 reference

4 December 2017

Zhi Liu

8

1 reference

4 December 2017

Thomas A Comery

9

1 reference

4 December 2017

Karen L Marquis

10

1 reference

4 December 2017

Sharon Rosenzweig-Lipson

11

1 reference

4 December 2017

20 December 2008

1 reference

4 December 2017

12

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

4 December 2017

204

1 reference

4 December 2017

1

1 reference

4 December 2017

37-48

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-008-1433-z

4 December 2017

0 references

cites work

The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment

1 reference

12 December 2020

What's atypical about atypical antipsychotic drugs?

1 reference

12 December 2020

On the importance of mesolimbic mechanisms for the control of apomorphine induced climbing behaviour in the mouse [proceedings]

1 reference

12 December 2020

Why do schizophrenic patients refuse to take their drugs?

1 reference

12 December 2020

Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications

1 reference

12 December 2020

Pharmacological Specificity of Conditioned Avoidance Response Inhibition in Rats: Inhibition by Neuroleptics and Correlation to Dopamine Receptor Blockade

1 reference

12 December 2020

Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice

1 reference

12 December 2020

Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.

1 reference

12 December 2020

1 reference

12 December 2020

Atypical antipsychotics and weight gain--a systematic review

1 reference

12 December 2020

Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability

1 reference

12 December 2020

Tardive dyskinesia: prevalence, incidence, and risk factors

1 reference

12 December 2020

Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity

1 reference

12 December 2020

Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo

1 reference

12 December 2020

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

1 reference

12 December 2020

Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia

1 reference

12 December 2020

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

1 reference

12 December 2020

Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder

1 reference

12 December 2020

Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology

1 reference

12 December 2020

The effect of clozapine on extracellular dopamine levels in the shell subregion of the rat nucleus accumbens is reversed following chronic administration: comparison with a selective 5-HT(2C) receptor antagonist

1 reference

12 December 2020

Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study

1 reference

12 December 2020

Metabolic effects associated with atypical antipsychotic medications

1 reference

12 December 2020

Antipsychotic-induced weight gain and therapeutic response: a differential association.

1 reference

12 December 2020

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

1 reference

12 December 2020

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

1 reference

12 December 2020

Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan

1 reference

12 December 2020

Effects of atypical antipsychotics on weight and serum lipid levels

1 reference

12 December 2020

WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

A two-year prospective study of treatment compliance in patients with schizophrenia

1 reference

12 December 2020

Medication noncompliance in schizophrenia: codification and update

1 reference

12 December 2020

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.

1 reference

12 December 2020

Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents

1 reference

12 December 2020

Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene

1 reference

12 December 2020

Differences in the nature of the stereotyped behaviour induced by aporphine derivatives in the rat and in their actions in extrapyramidal and mesolimbic brain areas

1 reference

12 December 2020

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

12 December 2020

Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.

1 reference

12 December 2020

The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management

1 reference

12 December 2020

10.1007/S00213-008-1433-Z

Identifiers

DOI

1 reference

4 December 2017

1 reference